WITHDRAWN: Acidic oligosaccharide sugar chain (AOSC) transport through the blood–brain barrier in glucose transporter 1 (GLUT-1)-dependent pathway
Xiu-Li Guo,Zhao Yang,Qin Nie,Wei Xia,Jin-Ping Li,Xian-Liang Xin,Mei-Yu Geng
DOI: https://doi.org/10.1016/j.brainresbull.2006.04.007
IF: 3.715
2006-01-01
Brain Research Bulletin
Abstract:The accessibility of marine-derived acidic oligosaccharide sugar chain (AOSC), an anti-Alzheimer's drug candidate, to the blood–brain barrier and the related mechanism was studied. Rabbits were treated with AOSC (mixed with tritium-labeled AOSC, 10.7 μCi/kg) via the intravenous and oral routes at 80 and 200 mg/kg, respectively. The concentrations of AOSC in the cerebrospinal fluid (CSF) and plasma and the CSF/plasma ratio (CPR) were detected. Results showed that AOSC was enriched in the CSF at 2 h following the intravenous and oral administration, with CPR of 4.41% and 3.22%, respectively. Further studies indicated that the transport mechanism of AOSC to the blood–brain barrier (BBB) was mediated via type 1 glucose transporter (GLUT-1). Keywords Acidic oligosaccharide sugar chain CSF GLUT-1 Rabbits RBC 1 Introduction Although the exact pathogenesis of Alzheimer's disease (AD) remains to be fully defined, several pharmacological strategies for preventing and treating AD are under active investigation. More recently, drug designing has targeted molecular events involved in the pathogenesis of AD including β-amyloid (Aβ) and neurofibrillary tangle formation [16,21,22] . Acidic oligosccharide sugar chain (AOSC), a marine-derived acidic oligosaccharide which belongs to (glycosaminoglycans) GAGs family, was extracted from brown algae Echlonia Kurome Okam by enzymatic depolymerization. It bears mannuronate block, with the average molecular weight approximately 1300 Da. In vivo studies have demonstrated that AOSC can attenuate the behavioral symptoms of Alzheimer type in rodent models induced by scopolamine and Aβ1-40 [13,6] . This indicated that AOSC might cross the blood–brain barrier (BBB) to exhibit its potential therapeutic value in AD. The BBB endothelial cells have a low number of vesicles and lack fenestrations, particularly the presence of tight junctions, so the entry into the brain is limited for many potential therapeutic agents such as neuropeptides and oligosaccharides. Recent studies have used the mammalian facilitative glucose transporter to deliver “natural” peptide messages across the blood–brain barrier. The rationale for these drugs transported actively into the brain is conjugating the native peptide to β- d -glucose to help the peptide molecule across the BBB by GLUT-1 [23,3] . Other studies have shown that heparin oligosaccharides (known as a kind of GAGs) and C3 (ultra low molecular weight heparin) can pass through BBB in a molecular weight dependent manner and inhibit amyloid β precursor protein processing, favoring their potential effects against AD [16,18] . The mechanism of this transportation is still not clear, it is proposed that it is likely to be a GLUT-1-involved event. AOSC contains pure form 1, 4-β- d -mannuronate, is also of polyanion structure which is similar to heparin oligosaccharides and C3. It would be interesting to see if GLUT-1 may also be a transporter mediating AOSC to cross the BBB. Recently, we have demonstrated that AOSC penetrate the BBB using a specific chemical method [9] and a SPR-based competitive inhibition immunoassay [10] . In this study, radiolabeled AOSC was used to further confirm the capacity of AOSC transporting across the BBB and consequently define the fashion of AOSC in cerebrospinal fluid (CSF). Furthermore, the transport mechanism of AOSC through the BBB was investigated. 2 Materials and methods 2.1 Materials AOSC was obtained from Institute of marine drug and food, Ocean university of China. The compound was provided as a white powder and was stored at room temperature. AOSC was degraded from polymannuronic acid by means of enzymatic depolymerization. [ 3 H]NaBH 4 was obtained from Amersham Biosciences. Sephadex™G-15 and Sepharose CL-4B was purchased from Amersham Bioscences, Uppsala, Sweden. Fluorescein-5-isothiocyanate (FITC), NaCNBH 4 , Tyramine (Tyr), cytochalasin B and phenyl methyl sulphonyl fluoride (PMSF), were purchased from Sigma, Saint Louis, MO, USA. Anti-GLUT-1 antibody was purchased from Adi, USA. 1209-RACKBETA (WALLAC)-liquid Scintillation Counter made in Finland. Male and female rabbits weighing from 1.5 to 2.5 kg were purchased from Animal Center of Shandong University (Certificate number: SCXK2002-0003, Shandong, China). All experiments were performed according to all guidelines on animal care. 2.2 Borohydride radiolabeling of AOSC [16] Sample (1 mg) of AOSC was dissolved in distilled water and adjusted pH to 9 using 0.01 M NaOH, final volume was 185 μL. The solution was reduced with 0.5 mCi of NaB 3 H 4 (Amersham Biosciences; specific activity, 55 Ci/mmol). The mixtures were left at room temperature for 15 h and were then adjusted (in a fume hood) first to pH 4 with 4 M acetic acid and then to pH 7 with 4 M NaOH. 3 H-labeled AOSC were isolated by gel chromatograph on a column (1 cm × 190 cm) of Sephadex G-15 (Amersham Biosciences, Sweden) in 0.2 M NH 4 HCO 3 . The pooled fractions were desalted by lyophilization. 2.3 Determination of CSF concentration of AOSC after a single intravenous injection and oral administration Rabbits were anesthetized with 3% sodium pentobarbital and treated with a single dose of venous and oral administration of AOSC at concentration of 80 and 200 mg/kg, respectively. The AOSC solution consisted of radioactively labeled AOSC (10.7 μCi/kg). The CSF samples were drawn out from the cisterna magna that is behind the cerebellum at 2 h after the administration. Blood samples were taken at the same time. The radioactive AOSC contents of plasma and CSF were measured using liquid scintillation spectrometry (Finland). Then the CSF/plasma (CPR) was calculated. 2.4 Separation of AOSC in the CSF after intravenous administration by sephadex G-15 After intravenous administration of AOSC (consisting of [ 3 H] AOSC, 10.7 μCi/kg) at 80 mg/kg, CSF samples were taken during 6 h. CSF sample and standard [ 3 H] AOSC sample were isolated by gel chromatograph on a column (1 cm × 100 cm) of Sephadex G-15 in 0.2 M NH 4 HCO 3 . Comparing the elution curve of CSF sample with one of standard [ 3 H] AOSC, the form of AOSC in CSF was identified. 2.5 Flow cytometry analysis Erythrocytes are a good source for studying the mammalian facilitative glucose carriers (GLUT-1), since they contain only a single membrane and high expression of GLUT-1 on membrane that has the same function with that on the BBB. Another advantage of human erythrocytes is that they are available from blood banks, so the cell harvest is easier than that of endothelial cells of the BBB. Therefore, erythrocytes were used to investigate the interaction of AOSC with GLUT-1 in this study. Erythrocytes of human peripheral blood prepared were incubated with or without FITC-labeled AOSC that was prepared according to the method established by our lab [17] at concentrations ranging from 100 to 800 mg/L for 10 s. After incubation, cells were washed with phosphate-buffered saline (PBS) three times and erythrocytes were gated and analyzed by flow cytometry (BD, USA), with a 488 nm laser excitation and a 530 nm emission filter. Thereafter, erythrocytes were incubated separately with or without glucose 400, 800, 1200 mg/L and FITC-labeled AOSC at a final concentration of 400 mg/L for 10 s. To further study the inhibitory effect of cytochalasin B on AOSC-FITC influx, erythrocytes were incubated with or without 5 mM cytochalasin B 10, 20, 50 μL for 30 min, followed by FITC-labeled AOSC at a final concentration of 400 mg/L for 10 s. Then cells were washed for three times with PBS and erythrocytes were gated and analyzed by flow cytometry. 2.6 Preparation and purification of erythrocytes membrane proteins Human erythrocyte “ghost” membrane was prepared by hypotonic lysis of outdated packed red cells (Bloodbank of Qingdao). The membrane was stripped of cytoskeleton by 1 mM EDTA, 1 mM PMSF and 0.02% NaN 3 , pH 7.5 at 4 °C. Then the supernatant fraction was centrifuged at 7000 × g for 30 min. The stripped membrane was harvested and then washed with NaOH at pH 11.0 to remove other extrinsic membrane proteins. Then membrane proteins were solubilized. Briefly, membrane fraction was resuspended in solubilization buffer containing 20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% (v/v) Triton X-100, 1 mM MgCl 2 , 1 mM CaCl 2 , 1 mM EDTA, 1 mM PMSF and stirred at 4 °C for 2 h. Then the suspension was centrifuged at 100,000 × g for 30 min and the supernatant containing membrane proteins was collected and dialyzed against 20 mM Tris–HCl (pH 7.4), containing 0.1% (v/v) Triton X-100 and 150 mM NaCl [12,7,19] . The proteincontent was determined by the method of Lowry. All operations were carried out at 4 °C. The purification of the solubilized membrane proteins was performed by applying to a AOSC-sepharose affinity column (1 cm × 6 cm, Sepharose CL-4B, Amersham Biosciences, Sweden) previously equilibrated with 20 mM Tris–HCl (pH 7.4), containing 0.1% (v/v) Triton X-100 and 150 mM NaCl and firstly washed with the same buffer, then eluted with linear gradient of 0.15–1.5 M NaCl in Tris buffer (pH 7.4) containing 0.1% (v/v) Triton X-100 at a flow rate of 0.5 mL/min. The elution was monitored at 280 nm for protein and estimated with 0.01% (w/v) Coomassie brilliant blue R-250 in ethanol, phosphoric acid and water (1:2:20, v/v/v) and the absorbance was measured at 595 nm with microplate reader [4,14] . Fractions were pooled and dialyzed against redistilled water, which followed by concentration. 2.7 Western blotting analysis Western blotting of the purified membrane proteins was conducted according to Towbin et al. [24] . Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of purified membrane proteins was performed in 15% gel. Then proteins bands separated on SDS-PAGE were transferred electrophoretically to nitrocellulose membranes at 200 mA for 5 h. Nitrocellulose membranes were blocked by 5% (w/v) BSA overnight at 4 °C, washed with PBS containing 0.05% (v/v) Tween 20, and incubated at 37 °C for 1 h with 1:100 diluted antibody of rabbit anti-mouse glucose transporter-1 (GLUT-1) (Adi, USA) and HRP-conjugated anti-Biotin-antibody. Blots were washed three times with buffer (10 min each) and then incubated with secondary antibody (HRP-conjugated mouse anti-rabbit-second antibody) at room temperature for 2 h. Blots were then washed three times (10 min each) with buffer, before exposure to equivalent volumes of enhanced chemiluminescence (ECL) detection reagents 1 and 2 (Amersham Biosciences). Blots were then wrapped in clingfilm and exposed to Hybond-ECL X-ray film for between 30 s and 2 min. Densitometry was performed using a SYNGENE Calibrated Imaging Densitometer (USA) and data analyzed using GraphPdad PRISM. 2.8 Statistics Data were expressed as mean ± S.E.M. Student's t -test and analysis of variance (ANOVA) were performed by Statview to assess differences between the relevant control and each experimental group. P -values of <0.05, <0.01 were regarded as indicating statistical significance. The results shown were representative of triplicate separate experiments. 3 Results 3.1 The concentration of AOSC in CSF after intravenous and oral administration The radioactivity of 3 H-labeled AOSC we obtained was 0.95 × 10 9 cpm/mg. The results of the concentrations of AOSC in CSF were shown in Table 1 . After intravenous injection, the concentrations of AOSC were 2.653 ± 0.493 and 62.057 ± 8.632 μg/mL at 2 h in CSF and blood, respectively. The CPR is 4.41%. After oral administration, the concentrations of AOSC were 1.836 ± 0.077 and 46.406 ± 6.701 μg/mL in CSF and blood, respectively. The CPR is 3.22%. This indicated that AOSC penetrated the BBB effectively. 3.2 Separation curve of AOSC in CSF and standard [ 3 H] AOSC by sephadex G-15 The eluted profile was shown in Fig. 1 . The separation curve of standard 3 H-AOSC and CSF sample has the same peak fashion during 30–45 mL eluted volume. The analysis revealed that AOSC pass through the BBB without being metabolized. 3.3 Competitive inhibition of AOSC entry by glucose and cytochalasin B Firstly, the binding capacity of AOSC to erythrocytes was investigated using FITC-labeled AOSC. Flow cytometry analysis showed that the fluorescent intensity of erythrocytes in FITC-labeled AOSC group demonstrated strikingly stronger than that of the control group. And the increase in concentration (from 100 to 800 mg/L) with AOSC-FITC led to an increment in fluorescent intensity of erythrocytes gradually (from 2.173 ± 0.523 to 8.160 ± 0.944 a.u., the value is the difference between FITC-AOSC group and control group) ( Fig. 2 ). Results implicated that AOSC strongly bound to human erythrocytes in a concentration-dependent fashion. Then the interaction of AOSC and GLUT-1 on erythrocyte membrane was investigated by competitive inhibition test. Accordingly, the effects of AOSC on transporting function of GLUT-1 on erythrocytes were investigated. GLUT-1, a specific transporter of glucose, is potently and reversibly inhibited by a number of compounds that bind to the protein carriers much more tightly than glucose. Of them, cytochalasin B is preferentially important, because it binds to the transport system in the inner-gated channel [15] . Therefore, glucose and cytochalasin B were selected here to elucidate the involvement of AOSC in transporting function of GLUT-1. Uptake of AOSC-FITC by erythrocytes was competitively inhibited by glucose and cytochalasin B obviously ( P < 0.01). A 800 and 1200 mg/L of glucose exerted a remarkable blocking effect with inhibitory rate at 65.74% and 82.85%, respectively, and 20, 50 μM of cytochalasin B reached to inhibition rate at 41.68% and 57.07% ( Figs. 3 and 4 ). Results indicated that AOSC is closely involvement in transporting function of GLUT-1. 3.4 Identification of GLUT-1–AOSC interaction The finding that glucose and cytochalasin B can inhibit the AOSC-FITC flux prompted us to assume that AOSC may be mediated by GLUT-1 to cross the BBB. To confirm this hypothesis, fraction obtained with affinity chromatogram was then subjected to Western blotting with antibody specifically recognizing GLUT-1. Results showed that there was a clearly band at 110 kDa on the nitrocellulose membrane. Since the molecular weight of GLUT-1 is approximately 55 kDa, we estimated that this band is GLUT-1 dimer ( Fig. 5 ). 4 Discussion The human glucose transporter GLUT-1 is abundant in the BBB and erythrocytes, where it exhibits the same function that mediates the transport of the energy metabolite, glucose. The human erythrocyte, as comparable with the BBB, is a particularly abundant source of GLUT-1 consisting of 492 amino acids with a molecular weight of 54,117 Da. There are about 51,000 copies of GLUT-1 per erythrocyte [8] , which corresponds to 12 ± 3% (w/w) of all membrane proteins in membrane vesicles from erythrocytes. This feature will satisfy the needs for cell amounts and protein level for desired experiments. In fact, human erythrocytes represent a good material for studying the GLUT-1-involved events [2] . Therefore, in current study, we selected erythrocytes as a surrogate model to evaluate the possible mechanism involved in transportation of AOSC through the BBB. Using flow cytometry, we initially found that AOSC binds to erythrocytes in a concentration-dependent fashion. Notably, both glucose (the specific substrate of GLUT-1) and cytochalasin B (an inhibitor of GLUT-1) inhibit the uptake of AOSC into erythrocytes. All these findings indicate that the binding of AOSC to erythrocytes might be closely related to GLUT-1 on erythrocyte membrane. Further investigation using AOSC affinity chromatography and subsequent western blotting analysis indicated that AOSC binds to 110 kDa protein molecules which are identified as dimeric form of GLUT-1. Haneskog et al. [11] reported that the formed GLUT-1 complexes are not homogeneously monomeric and self-associate rapidly into dimmer or oligomer using the nonionic detergents, such as Octyl glucoside and Triton X-100, etc., though GLUT-1 is solubilized effectively in the kind of these detergents. In the present study, we selected the detergent Triton X-100 to treat erythrocytes ghosts for preparation of purified GLUT-1 in a functional form. In fact, GLUT-1 in dimmer or oligomer represents its functional form [1] . Burant and Bell [5] have shown that although the GLUT-1 is functional as monomer in heterologous expression systems such as Xenopus oocytes , it may also exist as oligomer, particularly tetramerization. Tetramerization may produce cooperative interactions that may serve to increase in catalytic activity [5,20] . Nevertheless, it is generally accepted that the GLUT-1 undergoes conformational changes at various state. Thus, it is not unexpected to get dimeric instead of the monomeric form of GLUT-1 under our experimental conditions. This result is likely attributed to the difference in concentration of SDS and protein, difference in detergent, ionic intensity, pH, etc. In summary, we have demonstrated for the first time that GLUT-1 molecule was the specific binding protein for AOSC in erythrocytes. Given that erythrocytes represent as a surrogate model of GLUT-1-involved transportation of BBB, it is likely to deduce that GLUT-1 was involved in the transportation of AOSC through the BBB. However, further elucidation of the GLUT-1 on the BBB using brain microvascular endothelial cells is needed. Acknowledgements This work was funded by the National Basic Research 973 Program Grant of China (2003CB716400), Natural Science Foundation of China Grants (A30472029), National High Technology Research and Development Program of China 863 Program Grant (2001AA620405). References [1] G.I. Bell C.F. Burant J. Takeda G.W. Gould Structure and function of mammalian facilitative sugar transporters J. Biol. Chem. 26 1993 19161 19164 [2] J.M. Boulter D.N. Wang Purification and characterization of human erythrocyte glucose transporter in decylmaltoside detergent solution Protein Expres. Purif. 22 2001 337 348 [3] F. Bourasset S. Cisternino J. Temsamani J.M. Scherrmann Evidence for an active transport of morphine-6-β- d -glucuronide but not P -glycoprotein-mediated at the blood–brain barrier J. Neurochem. 86 2003 1564 1567 [4] M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254 [5] C.F. Burant G.I. Bell Mammalian facilitative glucose transporters: evidence for similar substrate recognition sites in functionally monomeric proteins Biochemistry 31 1992 10414 10420 [6] Y. Fan J. Hu J. Li Z. Yang X. Xin J. Wang J. Ding M. Geng Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms Neurosci. Lett. 374 2005 222 226 [7] C. Geetha V. Deshpande Purification and characterization of fish liver ferritins Comp. Biochem. Phys. B 123 1999 285 294 [8] I. Gottschalk Y.M. Li P. Lundahl Chromatography on cells: analyses of solute interactions with the glucose transporter Glut1 in human red cells adsorbed on lectin-gel beads J. Chromatogr. B: Biomed. Sci. Appl. 739 2000 55 62 [9] X.L. Guo M.Y. Geng Y. Zhou Q. Nie Primary study of structure–activity relationship of transport of marine-derived sugar chains across blood–brain barrier by 3-phenylphenol colorimetry Asian J. Drug Metab. Ph. 4 2004 225 229 [10] X. Guo X. Xin L. Gan Q. Nie M. Geng The determination of the accessibility of acidic oligosaccharide sugar chain to blood–brain barrier using surface plasmon resonance Biol. Pharm. Bull. 1 2006 60 63 [11] L. Haneskog L. Andersson E. Brekkan A.K. Englund K. Kameyama L. Liljas E. Greijer J. Fischbarg P. Lundahl Monomeric human red cell glucose transporter (Glut1) in non-ionic detergent solution and a semi-elliptical torus model for detergent binding to membrane proteins Biochim. Biophys. Acta 1282 1996 39 47 [12] H.N. Hao W.D. Lyman HIV infection of fetal human astrocytes: the potential role of a receptor-mediated endocytic pathway Brain Res. 823 1999 24 32 [13] J. Hu M. Geng J. Li X. Xin J. Wang M. Tang J. Zhang X. Zhang J. Ding Acidic oligosaccharide sugar chain, a marine-derived acidic oligosaccharide, inhibits the cytotoxicity and aggregation of amyloid Beta protein J. Pharmacol. Sci. 95 2004 248 255 [14] R. Krauspe A. Scheer Coomassie brilliant blue G-250 dye-binding technique for determination of autolytic protein breakdown in Euglena gracilis and comparison to other methods of autolysis measurement Anal. Biochem. 153 1986 242 250 [15] R.M. Krupka R. Deves Looking for probes of gated channels: studies of the inhibition of glucose and choline transport in erythrocytes Biochem. Cell Biol. 64 1986 1099 1107 [16] B. Leveugle W. Ding F. Laurence M.P. Dehouck A. Scanameo R. Cecchelli H. Fillit Heparin oligosaccharides that pass the blood–brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide J. Neurochem. 70 1998 736 744 [17] F.C. Li M.Y. Geng Y.X. Li J. Li B.C. Miao H.S. Guan Studies on fluorescent labeling of marine sulfated polysaccharide 911 Chem. J. Chinese U. 9 2002 1704 1708 [18] Q. Ma B. Dudas M. Hejna U. Cornelli J.M. Lee S. Lorens R. Mervis I. Hanin J. Fareed The blood–brain barrier accessibility of a heparin-derived oligosaccharides C3 Thromb. Res. 105 2002 447 453 [19] S. Maeda Y. Kashiwabara Purification and properties of a membrane-bound phospholipase B from Mycobacterium lepraemurium Biochim. Biophys. Acta 1303 1996 31 38 [20] R.J. Naftalin R.J. Rist Re-examination of hexose exchanges using rat erythrocytes: evidence inconsistent with a one-site sequential exchange model, but consistent with a two-site simultaneous exchange model Biochim. Biophys. Acta 1191 1994 65 78 [21] M.B. Podlisny B.L. Ostaszewski S.L. Squazzo E.H. Koo R.E. Rydell D.B. Teplow D.J. Selkoe Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfated-stable oligomers in cell culture J. Biol. Chem. 270 1995 9564 9570 [22] A.D. Snow M.G. Kinsella E. Parks R.T. Sekiguchi J.D. Miller K. Kimata T.N. Wight Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin and versican) to the beta amyloid protein of Alzheimer's disease Arch. Biochem. Biophys. 320 1995 84 95 [23] R. Tomatis M. Marastoni G. Balboni R. Guerrini A. Capasso L. Sorrentito V. Santagada G. Caliendo L.H. Lazarus S. Salvadori Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides J. Med. Chem. 40 1997 2948 2952 [24] H. Towbin T. Staehelin J. Gordon Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications Proc. Natl. Acad. Sci. U.S.A. 76 1979 4350 4354